Anthrasil (Cangene Corporation)


Welcome to the PulseAid listing for the Anthrasil drug offered from Cangene Corporation. This pharmaceutical is classified as a PLASMA DERIVATIVE. Below, you can view the details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same PLASMA DERIVATIVE drug type category.

LABELER NAME / MANUFACTURER: Cangene Corporation
NON-PROPRIETARY NAME: Anthrax immune globulin (human)
SUBSTANCE NAME: ANTHRAX IMMUNE GLOBULIN HUMAN
TYPE: PLASMA DERIVATIVE
PHARMA CLASS:
ROUTE: INTRAVENOUS
DOSAGE FORM: LIQUID
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2015-10-05
END MARKETING DATE: 0000-00-00


Anthrasil PLASMA DERIVATIVE Details:

Item DescriptionAnthrasil from Cangene Corporation
LABELER NAME: Cangene Corporation
DEA SCHEDULE:
ACTIVE STRENGTH: 60([iU]/35mL)
START MARKETING DATE: 2015-10-05
END MARKETING DATE: 0000-00-00
PRODUCT ID: 60492-0249_97cc9a89-6fe0-424e-82d1-0cf9d19444db
PRODUCT NDC: 60492-0249
APPLICATION NUMBER: BLA125562

Other ANTHRAX IMMUNE GLOBULIN HUMAN Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Cangene CorporationAnthrasil